Patient P-02233
Synthetic patientMETA-24 · Day 168 · 55–64 · F · baseline S16Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Stable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Stable
Discontinuation risk
41%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S16
- Day 122 CR-01 recommended — Clinician Review CR-01
- Day 123 Patient accepted — Started CR-01 in the companion
- Day 128 Deterioration detected before clinical escalation — Clinician Review CR-01
- Day 132 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 132.
Primary contributors, last 14 days
- GI instability-5
- Inflammatory activity-4
- Nutritional resilience-2
What helped?
- Clinician Review CR-01Day 122Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
57%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 87% showed improvement
- median effect visible after 8 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable43 min
stable · -0.6 vs previous 14 d
Sleep duration
Wearable6.7 h
worsening · -0.4 vs previous 14 d
Energy level
Daily log3.6/10
worsening · -0.9 vs previous 14 d
Steps
Wearable4,210
worsening · -158 vs previous 14 d
GI burden
Companion43.7/100
worsening · +6.1 vs previous 14 d
Adherence
Companion77.2 %
worsening · -9.5 vs previous 14 d
Sleep quality
Wearable40.1/100
worsening · -5.2 vs previous 14 d
Glucose, CGM daily mean
CGM142 mg/dL
stable · +2.9 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 54 from the failing basin, 36 from restoration.
Good elements to keep
- Clinician Review CR-01intervention · steering +38.6
- Protein (supports)perturbation · steering +9.6
- Daily walks resumedperturbation · steering +3.3
- Proteinsupporter · GI -5.7 next day
Main detractors to watch
- Low butyrate capacityhidden · steering -17.5
- Poor metabolizerhidden · steering -12.7
- Caffeineperturbation · steering -9.2
- Dietary fat loadperturbation · steering -8.3
- Caffeinedetractor · GI +5.1 next day
- Dietary fat loaddetractor · GI +4.3 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-5.7supporter · 95%
- Caffeine+5.1detractor · 95%
- Dietary fat load+4.3detractor · 95%
- Ultra-processed food+4.2detractor · 95%
- Simple carbohydrates+3.4detractor · 90%
- Histamine load-1.8no signal · 35%
- Alcohol+1.1no signal · 17%
- Insoluble fibre-0.6no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 43/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 44
- Inflammatory signalling ↓50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 45
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
- Autonomic recovery ↓25
- WearableResting HR 73 bpm
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 2.6 · butyrate capacity 43/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 49 ms
- Sleep
- 6.4 h
- Steps
- 3,523
- Resting HR
- 73 bpm
Daily log: GI score 44, nutritional resilience 47, adherence 77.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02398 | 46% | S06 | GI-04 | improved | 63 |
| P-02009 | 44% | S08 | CR-01 | improved | 64 |
| P-02078 | 43% | S04 | — | — | 56 |
| P-02054 | 42% | S01 | CR-01 | improved | 57 |
| P-02154 | 41% | S16 | CR-01 | improved | 57 |
| P-02240 | 40% | S20 | GI-04 | improved | 57 |
| P-02309 | 40% | S09 | — | — | 67 |
| P-02321 | 39% | S17 | GI-04 | improved | 54 |
| P-02252 | 38% | S02 | — | — | 65 |
| P-02084 | 37% | S11 | GI-04 | no change | 58 |
| P-02433 | 37% | S07 | GI-04 | improved | 61 |
| P-02530 | 37% | S07 | — | — | 67 |